Predicted Trait | |
Reported Trait | Alzheimer’s Disease |
Mapped Trait(s) | Alzheimer's disease (EFO_0000249) |
Score Construction | |
PGS Name | PHS |
Variants | |
Original Genome Build | NR |
Number of Variants | 31 |
Development Method | |
Name | Hazard model with stepwise selection of SNP inclusion |
Parameters | SNPs eligible for inclusion had a significane of p < 10−5 |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000016 |
Citation (link to publication) | Desikan RS et al. PLoS Med (2017) |
Study Identifiers | Sample Numbers | Sample Ancestry |
---|---|---|
GWAS Catalog: GCST002245 EuropePMC: 24162737 |
[
|
European |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|
Cases are patients with clinically diagnosed AD and compared to cognitively normal older individuals | — | [ ,
40.19 % Male samples |
— | European | — | ADGC | ADGC Phase 1 |
PGS Performance Metric ID (PPM ID) |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM000053 | PSS000036 | PGP000016 Desikan RS et al. (2017) | Reported Trait: Alzheimer disease | — | — | r (correlation between between binned quantiles of PHS-predicted and empirical age of AD onset): 0.9 | APOE risk alleles (e2 and e4), age, sex, genetic PCs 1-5 | — |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000036 | Cases are patients with clinically diagnosed AD and compared to cognitively normal older individuals | — | [ ,
40.51 % Male samples |
— | European | — | ADGC | ADGC Phase 2 |